Amgen Inc. (AMGN)

205.54
0.44 0.21
NASDAQ : Health Technology
Prev Close 205.10
Open 204.53
Day Low/High 204.11 / 205.20
52 Wk Low/High 163.31 / 206.62
Volume 178.81K
Avg Volume 2.38M
Exchange NASDAQ
Shares Outstanding 647.27M
Market Cap 132.76B
EPS 2.70
P/E Ratio 55.28
Div & Yield 5.28 (2.51%)

Latest News

Amgen And Los Angeles County Announce Collaboration To Support Life Science Innovation Hub - BioLA

Amgen And Los Angeles County Announce Collaboration To Support Life Science Innovation Hub - BioLA

Amgen's David Piacquad to Join BioLA Board of Directors

Spirit Airlines, Southwest, Amgen: 'Mad Money' Lightning Round

Spirit Airlines, Southwest, Amgen: 'Mad Money' Lightning Round

Jim Cramer weighs in on Spirit Airlines, Southwest, Amgen, Biogen Idec, Liberty Oilfield Services, The Chefs Warehouse, Under Armour and more.

Reasons for This Rally: Cramer's 'Mad Money' Recap (Tuesday 9/18/18)

Reasons for This Rally: Cramer's 'Mad Money' Recap (Tuesday 9/18/18)

Jim Cramer says news on tariffs, FANG stocks, positive research, and the corporate outlook are fueling a stock market surprise.

The Truth About Trade: Cramer's 'Mad Money' Recap (Monday 9/17/18)

The Truth About Trade: Cramer's 'Mad Money' Recap (Monday 9/17/18)

Jim Cramer says Wall Street isn't very worried about tariffs. He highlights the stocks with China exposure and looks at the potential impact.

PayPal, Senseonomics, Idexx Laboratories: 'Mad Money' Lightning Round

PayPal, Senseonomics, Idexx Laboratories: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at PayPal, Senseonomics, Idexx Laboratories, Sonos, Denbury Resources, Apptio, Invitae, Wayfair, JD.com, and McDonald's.

World's Largest Alzheimer's Survey Reveals Most Adults Believe A Cure Will Be Developed In Their Lifetime

World's Largest Alzheimer's Survey Reveals Most Adults Believe A Cure Will Be Developed In Their Lifetime

From a Sample of Over 10,000 Adults, 62 Percent are Worried They may Develop Alzheimer's Disease and 91 Percent Believe the Solution to Tackling Diseases Lies in Medical Research(1)

We Remain Bullish on Amgen Despite FDA's Approval of Competing Drug From Teva

Amgen's migraine prevention drug Aimovig is understood to be superior to Teva's Ajovy.

Jim's Daily Rundown

Jim discusses a number of stocks, including Amgen, PayPal and Salesforce.

Teva Shares Pop as FDA Approves Its Migraine Drug

Teva Shares Pop as FDA Approves Its Migraine Drug

Ajovy is the second anti-calcitonin gene-related peptide (CGRP) drug approved by the FDA to prevent migraines.

Weekly Roundup

The Trump administration has invited Chinese officials to a new round of trade negotiations later this month.

Amgen Becomes #18 Most Shorted Nasdaq 100 Component, Replacing Ctrip.com International

Amgen Becomes #18 Most Shorted Nasdaq 100 Component, Replacing Ctrip.com International

The most recent short interest data has been released for the 08/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Weekly Roundup

Investors wrapped up a volatile week on Wall Street.

Amgen To Present At The Morgan Stanley Global Healthcare Conference

Amgen To Present At The Morgan Stanley Global Healthcare Conference

THOUSAND OAKS, Calif., Sept.

Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype

Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype

Designation Supported by Phase 2b PATHWAY Data That Demonstrated Tezepelumab Significantly Reduced Asthma Exacerbations Compared to Placebo in Severe Asthma Patients

Tech Doesn't Have Good Defense: Cramer's 'Mad Money' Recap (Thursday 9/6/18)

Tech Doesn't Have Good Defense: Cramer's 'Mad Money' Recap (Thursday 9/6/18)

Jim Cramer, celebrating the opening of the NFL season, says this is just another day of total tech mayhem.

United Parcel Service, TJX Companies: 'Mad Money' Lightning Round

United Parcel Service, TJX Companies: 'Mad Money' Lightning Round

Jim Cramer takes a look at United Parcel Service, TJX Companies, Anheuser-Busch InBev, Fiat Chrysler, AbbVie, Nvidia, Excelixis, Bank of America, Endo Pharmaceutical and more.

Updates on a Few Portfolio Names

We look at Amgen, Citigroup and WestRock.

Amgen And LabCentral Open Nomination Process For Lab Residency

Amgen And LabCentral Open Nomination Process For Lab Residency

An Opportunity for Start-Ups to be Awarded a Golden Ticket

Weekly Roundup

Markets pressed higher this week as the U.S. and Mexico came to an agreement on trade.

Novice Trade: Amgen

Novice Trade: Amgen

Amgen calls just look too cheap to pass up here.

Trimming Goldman Sachs

The time has come to right-size this large position and take some shares off the table.

Amgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib) Once-Weekly 70 Mg/m2 In Combination With Dexamethasone

Amgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib) Once-Weekly 70 Mg/m2 In Combination With Dexamethasone

Filing Based on Data From Phase 3 Head-to-Head A.R.R.O.W. Study

Here's Why You Should Invest in Immunotherapy Companies

Here's Why You Should Invest in Immunotherapy Companies

Immunotherapy may be the future of fighting cancer and companies are racing to capitalize on that. We spoke with the CEO of the Damon Runyon Cancer Research Foundation to find out why.

Weekly Roundup

Markets pushed higher this week with the S&P 500 hitting a record high and showing resilience through several politically volatile events.

Exiting PepsiCo, Trimming PayPal

The combination of these two sales on strength will replenish our cash position and provide us with additional flexibility.

Dropbox, XPO Logistics, Ford Motor: 'Mad Money' Lightning Round

Dropbox, XPO Logistics, Ford Motor: 'Mad Money' Lightning Round

Jim Cramer weighs in on Dropbox, XPO Logistics, Ford Motor Co., Acadia Pharmaceuticals, Avalara, and more.

TheStreet Quant Rating: B (Buy)